Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888336 | 0.87 | KDM4C (0.55) | KDM4CNR4A2EGLN1PTGER4PTGER2 | |
| SCHEMBL3877722 | 0.85 | EGLN1 (0.55) | KDM4CNR4A2EGLN1MRGPRX4PTGER4 | |
| SCHEMBL3873589 | 0.85 | HSP90AB1 (0.53) | KDM4CNR4A2EGLN1SRD5A2 | |
| SCHEMBL3877786 | 0.85 | KDM4C (0.45) | KDM4CEGLN1MRGPRX4MAOBTHRB | |
| SCHEMBL3874651 | 0.85 | EGLN1 (0.54) | KDM4CEGLN1MRGPRX4MAOBTHRB | |
| SCHEMBL3886892 | 0.84 | KDM4C (0.57) | KDM4CNR4A2EGLN1PTGER4PTGER2 | |
| SCHEMBL3874216 | 0.83 | EGLN1 (0.56) | EGLN1MRGPRX4PTGER4PTGER2MMP13 | |
| SCHEMBL3875988 | 0.81 | CYSLTR1 (0.55) | KDM4CMRGPRX4PTGER4PTGER2 | |
| SCHEMBL27605796 | 0.81 | NR4A2 (0.73) | NR4A2EGLN1MRGPRX4MAOBSRD5A2 | |
| SCHEMBL3875335 | 0.80 | RXRA (0.54) | NR4A2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | claimed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | claimed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | claimed |
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | FBP1, ALDOA, GYS2 | KDM4C 3197/4885NR4A2 3675/4885EGLN1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.